Researchers at Vanderbilt Center for Antibody Therapeutics entered an option agreement with Saravir Biopharma to develop human monoclonal antibodies designed to treat and prevent measles infection. The collaboration relies on antibodies originally isolated through prior work and aims to translate those findings into therapeutic candidates. While measles is preventable through vaccines, outbreaks continue to create urgent demand for treatment options, particularly for vulnerable populations and settings where immunization gaps widen. A monoclonal antibody program can offer a different risk-management tool than vaccine-driven strategies. The agreement structure indicates a pipeline-building approach in which academic antibody platforms are partnered with industry for development execution and commercialization path planning.